PCM
ENZY

Prelude Capital Management’s Enzymotec Ltd ENZY Stock Holding History

Prelude Capital Management’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,021
Closed -$39K – 1700
2015
Q4 		$39K Buy
+4,021
New +$38.1K 0.01% 1095
2014
Q1 		– Sell
-10,000
Closed -$270K – 2242
2013
Q4 		$270K Buy
+10,000
New +$238K 0.04% 531

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's ENZY Position: Q1 2016 in Review

Prelude Capital Management sold out of Enzymotec Ltd (ENZY) in Q1 2016, closing a stake of 4,021 shares — an estimated $39K sold.

Prelude Capital Management first reported a position in ENZY in Q4 2013 and held it in 2 quarters. The position peaked at $270K in Q4 2013. 30 funds tracked by Wall St. Rank hold ENZY as of Q1 2016.

  • Prelude Capital Management reported no remaining Enzymotec Ltd position as of Q1 2016 after selling out during the quarter.
  • Prelude Capital Management sold 4,021 Enzymotec Ltd shares in Q1 2016, an estimated $39K.
  • Prelude Capital Management first reported a position in Enzymotec Ltd in Q4 2013 and held it in 2 quarters.
  • Prelude Capital Management's Enzymotec Ltd position peaked at $270K in Q4 2013.
  • 30 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q1 2016.

Based on Prelude Capital Management's 13F filing for Q1 2016, filed 16 May 2016.